Send to

Choose Destination
See comment in PubMed Commons below
Mol Clin Oncol. 2014 Sep;2(5):858-864. Epub 2014 Jun 23.

Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: A network meta-analysis of randomised clinical trials.

Author information

Department of Radiation Oncology, Tainan Municipal An-Nan Hospital-China Medical University, Tainan 709, Taiwan ; Hsin Sheng College of Medicine Care and Management, Taoyuan 325, Taiwan.
Hsin Sheng College of Medicine Care and Management, Taoyuan 325, Taiwan ; Department of Pharmacy, Tainan Municipal An-Nan Hospital-China Medical University, Tainan 709, Taiwan.
School of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan.


This network meta-analysis aimed to compare the clinical efficacy and safety among 7 newer targeted agents for the treatment of metastatic renal cell carcinoma (mRCC). All randomised clinical trials (RCTs) of targeted therapeutic drugs for mRCC were included. The study selection, data extraction and quality assessment were performed independently by two reviewers. The analysis evaluated efficacy outcomes [improvement in the median progression-free survival (PFS)] and safety outcomes (number of withdrawals due to adverse events). The network analysis included direct and indirect analyses. The quality of the selected studies was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) method. We identified 7 articles eligible for inclusion in the study. The direct comparison of the targeted agents indicated better efficacy in terms of longer PFS, but worse safety (more withdrawals due to adverse events). The indirect analysis demonstrated that axitinib was significantly more effective compared to panzopanib; sunitinib was superior to sorafenib and temsirolimus regarding efficacy outcome, without any statistically significant difference in the safety outcome. The results of the quality assessment indicated moderate scores using the GRADE method. In conclusion, the result of this network analysis suggested that sunitinib and axitinib may be more clinically efficient and axitinib is associated with a lower risk of adverse events compared to sorafenib, pazopanib and temsirolimus.


GPU-Enabled Many-Task Computing; hazard ratio; indirect treatment comparisons; metastatic renal cell carcinoma; mixed treatment comparisons; progression-free survival; serious adverse event; targeted therapy

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center